In a study of the effect of erlotinib on non-small cell lung cancer (NSCLC) xenograft samples, conventional Western blot analysis indicated that EGFR Y1068 was completely dephosphorylated upon treatment of erlotinib, a tyrosine kinase inhibitor, whereas ERK1/2 appeared to be only partly dephosphorylated (Figure 3). Here, MAPK3 is linked to non-small cell lung carcinoma.